Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine

Xiaorong Gu, PhD, Rita Tohme, PhD, Benjamin K. Tomlinson, MD, Lisa Durkin, Caroline Schuerger, Asmaa M Zidan, MB, BCh, Tomas Radivoyevitch, PhD, Hetty E. Carraway, MD MBA, Ronald Sobecks, MD, Betty K. Hamilton, MD, Alan Lichtin, MD, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2019) 134 (Supplement_1): 537.

https://doi.org/10.1182/blood-2019-125823

Published: 2019

Journal Articles

Hematologic Malignancies Exhibit Selective Vulnerability to Inhibition of De Novo Pyrimidine Biosynthesis By AG-636, a Novel Inhibitor of Dihydroorotate Dehydrogenase in Phase 1 Clinical Trials

Danielle Ulanet, Victor Chubukov, PhD, John Coco, BS, Gabrielle McDonald, PhD, Mya Steadman, BA, Rohini Narayanaswamy, MS, Sebastien Ronseaux, PhD, Sung Choe, PhD, Tabea Erdmann, PhD, Kevin Truskowski, BS, Kavitha Nellore, PhD, Siva Sanjeeva Rao, PhD, Hosahalli Subramanya, PhD, Georg Lenz, MD, Michael Cooper, MD, Josh Murtie, PhD, Kevin Marks, PhD

Blood (2019) 134 (Supplement_1): 1570.

https://doi.org/10.1182/blood-2019-123471

Published: 2019

Journal Articles

Discovery of a Novel Dihydroorotate Dehydrogenase Inhibitor That Induces Differentiation and Overcomes Ara-C Resistance of Acute Myeloid Leukemia Cells

Satoshi Kitazawa, PhD, Yukiko Ishii, PhD, Keiko Makita-Suzuki, Koichi Saito, PhD, Kensuke Takayanagi, Hiromi Sugihara, Shun Matsuda, PhD, Takayuki Yamakawa, PhD, Yasuhiro Tsutsui, Tadashi Tanaka, Tomohisa Hatta, PhD, Tohru Natsume, PhD, Toru Kondo, PhD, Yuichi Ishikawa, MD PhD, Shinji Hagiwara, PhD, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 2663.

https://doi.org/10.1182/blood-2019-121869

Published: 2019

Journal Articles

AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study

Scott F. Huntington, MD MPH, Avyakta Kallam, MD, Frank G. Basile, MD, Danielle Ulanet, Huansheng Xu, PhD, Feng Yin, PhD, Michelle Mobilia, BS, Michael Cooper, MD, Bijal Shah, MD, John P. Leonard, MD, Gottfried R. von Keudell, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 1286.

https://doi.org/10.1182/blood-2019-123420

Published: 2019

Journal Articles

Transcriptional Regulation of Coenzyme Q Biosynthesis By TIF1γ Drives Erythropoiesis

Marlies P. Rossmann, MD PhD, Karen Hoi, Victoria Chan, Julie R. Perlin, PhD, Elliott J. Hagedorn, PhD, Brian J. Abraham, PhD, Song Yang, PhD, Lucas B. Sullivan, PhD, Curtis R. Warren, PhD, Sejal Vyas, PhD, Eugenia Custo-Creig, Bilguujin Dorjsuren, Chad Cowan, PhD, Marcia C. Haigis, PhD, Richard A. Young, PhD, Leonard I Zon, MD

Blood (2019) 134 (Supplement_1): 152.

https://doi.org/10.1182/blood-2019-126833

Published: 2019

Journal Articles

Targeting Critical Kinases and Anti-Apoptotic Molecules Overcomes Steroid Resistance in Infant MLL-Rearranged Leukemia

Anne Pieta De Groot, Yoriko Saito, MD, Eiryo Kawakami, Mari Hashimoto, Yuki Aoki, Rintaro Ono, MD PhD, Ikuko Ogahara, Saera Fujiki, Akiko Kaneko, Takashi Watanabe, PhD, Masatoshi Takagi, MD PhD, Daisuke Tomizawa, MD PhD, Katsuyoshi Koh, MD, Mariko Eguchi, MD, Eiichi Ishii, MD PhD, Osamu Ohara, Leonard Shultz, PhD, Shuki Mizutani, Fumihiko Ishikawa, MD PhD

Blood (2019) 134 (Supplement_1): 3885.

https://doi.org/10.1182/blood-2019-129719

Published: 2019

Journal Articles

Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia

Valentina Gaidano, MD, Paola Circosta, PhD, Alessandro Cignetti, MD PhD, Mohammad Houshmand, Nicoletta Vitale, PhD, Stefano Sainas, PhD, Agnese Pippione, PhD, Manuela Marraudino, PhD, Brigitta Bonaldo, MD, Marta Giorgis, PhD, Donatella Boschi, PhD, Marco Lucio Lolli, PhD, Giuseppe Saglio, MD

Blood (2019) 134 (Supplement_1): 3942.

https://doi.org/10.1182/blood-2019-128085

Published: 2019

Journal Articles

The Distinctive Metabolic Environment of the Bone Marrow Niche Drives Leukemia Chemoresistance

Nick van Gastel, PhD, Jessica B. Spinelli, PhD, Azeem Sharda, MS, Amir Schajnovitz, PhD, Ninib Baryawno, PhD, Catherine S Rhee, PhD, Toshihiko Oki, MD PhD, Eliane Grace, Heather J. Soled, Charles Vidoudez, PhD, Sunia A. Trauger, PhD, Marcia C. Haigis, PhD, David T. Scadden, MD

Blood (2019) 134 (Supplement_1): 3725.

https://doi.org/10.1182/blood-2019-124789

Published: 2019

Journal Articles

Identification of Genetic Vulnerabilities and Synthetic-Lethal Targets in NSD2-High Multiple Myeloma

Amin Sobh, PhD, Charlotte Kaestner, Alberto Riva, PhD, Jonathan D. Licht, MD

Blood (2019) 134 (Supplement_1): 3757.

https://doi.org/10.1182/blood-2019-125951

Published: 2019

Journal Articles

Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and i n Vivo

Zhihong Zeng, Natalia Baran, PhDMD, Sergej Konoplev, Antonio Cavazos, Qi Zhang, Vinitha Mary Kuruvilla, MSc, Philip Lorenzi, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Courtney D. DiNardo, MDMSc, Joshua Murtie, Danielle Ulanet, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3911.

https://doi.org/10.1182/blood-2019-125469

Published: 2019

Journal Articles

Synergistic Effect of DHODH Inhibitor PTC299 with DNA Demethylating Agent Decitabine in Myelodysplastic Syndromes

Kensuke Kayamori, Cheng Zhong, Daisuke Shinoda, MD, Shuhei Koide, PhD, Motohiko Oshima, PhD, Yaeko Nakajima-Takagi, PhD, Naoya Mimura, MD PhD, Ryoji Ito, Kaoru Tohyama, MD PhD, William Lennox, Marla Weetall, PhD, Josephine Sheedy, BS, MSc, Emiko Sakaida, MD PhD, Koutaro Yokote, MD PhD, Atsushi Iwama, MD PhD

Blood (2019) 134 (Supplement_1): 5407.

https://doi.org/10.1182/blood-2019-125200

Published: 2019

Journal Articles

Loss of FLT3 Sensitizes Myeloid Cells to Differentiation Via DHODH Inhibition

Amy N Sexauer, MD PhD, Brian Do, David B Sykes, MD PhD

Blood (2019) 134 (Supplement_1): 2712.

https://doi.org/10.1182/blood-2019-128910

Published: 2019

Journal Articles

Differential Genome-Wide Mutational Patterns in Indolent B-Cell Lymphomas

Julieta Haydee Sepulveda Yanez, MSc, Diego Alvarez, MSc, Jose Fernandez-Goycoolea, Cornelis A.M. van Bergen, PhD, Hendrik Veelken, MD PhD, Marcelo A. Navarrete, PhD

Blood (2018) 132 (Supplement 1): 4102.

https://doi.org/10.1182/blood-2018-99-116174

Published: 2018

Journal Articles

DHODH Inhibitors in the Treatment of Acute Myeloid Leukemia: Defining the Mechanism of Action and the Basis of the Metabolic Therapeutic Window

Peggy P. Hsu, MD PhD, Youmna Kfoury, PhD, Najihah Aziz, Jenna Elkhoury, Brittany Hallgren, David T. Scadden, MD, Matthew Vander Heiden, MD PhD, David B Sykes, MD PhD

Blood (2018) 132 (Supplement 1): 2716.

https://doi.org/10.1182/blood-2018-99-113387

Published: 2018

Journal Articles

Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity

Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Chin Hin Ng, MD MRCP, Ashish Bajel, MBBS, FRACP, FRCPA, William YK Hwang, MBBS, FRCP(London), MMed(Int MD, FAMS, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Mark McHale, B.S., PhD, Chih-Yi Hsieh, MD, Hsuan-Jen Shih, MD, Nicola McIntyre, PhD, Jamie Kwek, Wei-Ling Chang, PhD, Bertil Lindmark, MD PhD

Blood (2018) 132 (Supplement 1): 2676.

https://doi.org/10.1182/blood-2018-99-110570

Published: 2018

Journal Articles

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study

Michael Rosenzweig, Joycelynne Palmer, Ni-Chun Tsai, Ralf Buettner, PhD, Lupe Duarte, Myo Htut, Chatchada Karanes, Nitya Nathwani, MD, Flavia Pichiorri, PhD, Firoozeh Sahebi, Tim Synold, Xiwei Wu, James F Sanchez, Amrita Krishnan, MD, Stephen J Forman, Steven T Rosen

Blood (2018) 132 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2018-99-120042

Published: 2018

Journal Articles

ASLAN003, a Novel and Potent Dihydroorotate Dehydrogenase (DHODH) Inhibitor, Induces Differentiation of Acute Myeloid Leukemia

Jianbiao Zhou, MD,PhD, Jessie Yiying Quah, B.S., Jing Yuan Chooi, BSc, Sabrina Hui-Min Toh, B.S., Yvonne Ng, B.S., Baohong Lin, B.S., Motomi Osato, MD, PhD, Qihui Seet, B.S., PhD, A.G. Lisa Ooi, B.S., PhD, Bertil Lindmark, MD PhD, Mark McHale, B.S., PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS

Blood (2018) 132 (Supplement 1): 4047.

https://doi.org/10.1182/blood-2018-99-114392

Published: 2018

Journal Articles

Metabolic Profiling Identifies De Novo Nucleotide Synthesis As a Potential Metabolic Vulnerability for Targeted Therapy Against Mantle Cell Lymphoma

Yixin Yao, PhD, Yang Liu, PhD, Hui Guo, PhD, Makhdum Ahmed, MD PhD MPH, Shabnam Bhuiyan, MSc, Krystle Nomie, PhD, Liang Zhang, MD PhD, Michael Wang, MD

Blood (2018) 132 (Supplement 1): 2945.

https://doi.org/10.1182/blood-2018-99-112192

Published: 2018

Journal Articles

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: A Phase 1 Trial

Michael Rosenzweig, MD, Joycelynne M. Palmer, PhD, Ni-Chun Tsai, MS, Ralf Buettner, PhD, Lupe Duarte, Myo Htut, Chatchada Karanes, Nitya Nathwani, Flavia Pichiorri, PhD, Firoozeh Sahebi, George Somlo, Tim Synold, PhD, Xiwei Wu, PhD, Amrita Krishnan, MD, Stephen J. Forman, MD FACP, Steven T. Rosen, MD

Blood (2017) 130 (Supplement 1): 3144.

https://doi.org/10.1182/blood.V130.Suppl_1.3144.3144

Published: 2017

Journal Articles

Ruxolitinib in Combination with Vorinostat Suppresses Tumor Growth and Alters the Metabolic Phenotype in Haematological Diseases

Monica Civallero, PhD, Maria Cosenza, MS, Sandra Marmiroli, MS, Samantha Pozzi, MD, Stefano Sacchi, MD

Blood (2017) 130 (Supplement 1): 5194.

https://doi.org/10.1182/blood.V130.Suppl_1.5194.5194

Published: 2017

NARROW

Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine

Hematologic Malignancies Exhibit Selective Vulnerability to Inhibition of De Novo Pyrimidine Biosynthesis By AG-636, a Novel Inhibitor of Dihydroorotate Dehydrogenase in Phase 1 Clinical Trials

Discovery of a Novel Dihydroorotate Dehydrogenase Inhibitor That Induces Differentiation and Overcomes Ara-C Resistance of Acute Myeloid Leukemia Cells

AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study

Transcriptional Regulation of Coenzyme Q Biosynthesis By TIF1γ Drives Erythropoiesis

Targeting Critical Kinases and Anti-Apoptotic Molecules Overcomes Steroid Resistance in Infant MLL-Rearranged Leukemia

Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia

The Distinctive Metabolic Environment of the Bone Marrow Niche Drives Leukemia Chemoresistance

Identification of Genetic Vulnerabilities and Synthetic-Lethal Targets in NSD2-High Multiple Myeloma

Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and i n Vivo

Synergistic Effect of DHODH Inhibitor PTC299 with DNA Demethylating Agent Decitabine in Myelodysplastic Syndromes

Loss of FLT3 Sensitizes Myeloid Cells to Differentiation Via DHODH Inhibition

Differential Genome-Wide Mutational Patterns in Indolent B-Cell Lymphomas

DHODH Inhibitors in the Treatment of Acute Myeloid Leukemia: Defining the Mechanism of Action and the Basis of the Metabolic Therapeutic Window

Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study

ASLAN003, a Novel and Potent Dihydroorotate Dehydrogenase (DHODH) Inhibitor, Induces Differentiation of Acute Myeloid Leukemia

Metabolic Profiling Identifies De Novo Nucleotide Synthesis As a Potential Metabolic Vulnerability for Targeted Therapy Against Mantle Cell Lymphoma

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: A Phase 1 Trial

Ruxolitinib in Combination with Vorinostat Suppresses Tumor Growth and Alters the Metabolic Phenotype in Haematological Diseases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only